PIP5K1B

PIP5K1B (phosphatidylinositol-4-phosphate 5-kinase type 1 beta) primarily catalyzes the phosphorylation of phosphatidylinositol 4-phosphate to generate phosphatidylinositol-4,5-bisphosphate (PI(4,5)P₂), a central lipid signaling molecule that regulates cytoskeletal dynamics, vesicle trafficking, and cell membrane organization^[1][2]. Mechanistically, PIP5K1B participates in phosphoinositide signaling pathways that modulate actin filament assembly and endosomal trafficking, thereby influencing cellular morphology and intracellular transport^[1][2]. In disease contexts, differential expression of PIP5K1B has been identified in lung adenocarcinoma, where it is implicated in dysregulated phosphatidylinositol signaling and cytoskeletal alterations^[2]. Compared with other PIP5KI isoforms, such as PIP5K1α and PIP5K1C, PIP5K1B exhibits unique tissue expression and substrate specificity, contributing distinctly to phosphatidylinositol-4,5-bisphosphate pools without compensating for PIP5K1C deficiencies in lysosomal or calcium signaling processes^[1][2]. Isoform-selective inhibitors of PIP5K1B, such as IITZ01 and its analogs NG-TZ-17 and NG-TZ-20, have been demonstrated to suppress hepatic cancer cell proliferation by modulating ROS-dependent autophagy and PI3K/AKT pathways, highlighting their potential as experimental tools for dissecting PIP5K1B-specific signaling^[3]. These findings position PIP5K1B as a functionally distinct lipid kinase with relevance to cytoskeletal regulation, cancer biology, and targeted pharmacological investigation.